Valuation: Jenburkt Pharmaceuticals Limited

Market Cap 382.19Cr 4.01Cr 3.59Cr 3.32Cr 3Cr 5.61Cr 5.7Cr 40Cr 16Cr 200.02Cr 15Cr 15Cr 633.52Cr P/E 2025
13.9x
P/E 2026 12.1x
Enterprise Value 337.36Cr 3.54Cr 3.17Cr 2.93Cr 2.65Cr 4.95Cr 5.03Cr 35Cr 14Cr 176.56Cr 13Cr 13Cr 559.21Cr EV / Sales 2025
2.82x
EV / Sales 2026 2.23x
Free-Float
38.82%
Yield 2025
1.78%
Yield 2026 2.17%
1 day-1.39%
1 week-0.70%
Current month-6.94%
1 month-6.94%
3 months-21.05%
6 months-18.22%
Current year-21.64%
1 week 848.35
Extreme 848.35
895
1 month 848.35
Extreme 848.35
1,045
Current year 848.35
Extreme 848.35
1,245
1 year 848.35
Extreme 848.35
1,321
3 years 586.9
Extreme 586.9
1,410
5 years 452.1
Extreme 452.1
1,410
10 years 243.2
Extreme 243.2
1,410
Manager TitleAgeSince
Chief Executive Officer - 22/10/2013
Director of Finance/CFO 74 24/09/2013
Chief Administrative Officer - 12/05/2025
Director TitleAgeSince
Chairman - 22/10/2013
Director/Board Member 74 07/09/2013
Director/Board Member 63 28/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%-0.70%-25.87%+36.56% 4.01Cr
+4.21%+11.43%+68.03%+150.84% 1,22400Cr
+1.18%+5.71%+47.51%+89.67% 66TCr
+1.83%+3.54%+29.61%+108.44% 51TCr
+0.44%+3.35%+54.38%+67.43% 39TCr
+2.41%+3.51%+74.28%+46.45% 36TCr
+1.50%+5.34%+36.37%+59.33% 30TCr
+6.53%+8.45%+10.86%+36.11% 27TCr
+2.43%+7.96%+62.41%+80.18% 25TCr
+3.37%+10.53%+45.62%+121.77% 21TCr
Average +2.18%+2.21%+40.32%+79.68% 41.77TCr
Weighted average by Cap. +2.58%+3.04%+51.88%+99.44%

Financials

2025 2026
Net sales 151.69Cr 1.59Cr 1.43Cr 1.32Cr 1.19Cr 2.23Cr 2.26Cr 16Cr 6.27Cr 79Cr 5.98Cr 5.85Cr 251.44Cr 168.74Cr 1.77Cr 1.59Cr 1.46Cr 1.33Cr 2.48Cr 2.52Cr 17Cr 6.97Cr 88Cr 6.65Cr 6.51Cr 279.7Cr
Net income 32Cr 33.67L 30.16L 27.82L 25.18L 47.08L 47.84L 3.32Cr 1.32Cr 17Cr 1.26Cr 1.24Cr 53Cr 35Cr 36.48L 32.67L 30.14L 27.28L 51.01L 51.83L 3.6Cr 1.43Cr 18Cr 1.37Cr 1.34Cr 58Cr
Net Debt -19Cr -20.21L -18.11L -16.7L -15.12L -28.27L -28.72L -1.99Cr -79.5L -10Cr -75.86L -74.25L -32Cr -45Cr -47.07L -42.16L -38.9L -35.2L -65.82L -66.89L -4.64Cr -1.85Cr -23Cr -1.77Cr -1.73Cr -74Cr
Projected Income Statement - Annual - Jenburkt Pharmaceuticals Limited
Logo Jenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited is an India-based company that is engaged in the business of manufacturing, producing, developing and marketing a range of branded pharmaceuticals and healthcare products. The Company offers pharmaceutical products for various therapeutic areas, including analgesic and antipyretics, anthelmintics, anti-arthritics, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer products, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. The Company's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets, Topcal-M Tablets, Powergesic, ZIX P Tablet, and others. The Company's manufacturing plant is in Sihor, Gujarat.
Employees
801
Date Price Change Volume
30/26/30 ₹854.00 -1.39% 86
29/26/29 ₹866.00 -3.01% 1,120
27/26/27 ₹892.90 +2.51% 76
26/26/26 ₹871.05 +1.28% 194
23/26/23 ₹860.00 -1.93% 53
  1. Stock Market
  2. Stocks
  3. JENBURPH Stock